Houston tech company is helping to scale breast cancer screening using IT solutions

tech detection

Through a partnership between two Houston companies, installing breast cancer screening technology is easier than ever. Getty Images

With October being National Breast Cancer Awareness Month, two Houston companies are working to provide a fast and accurate diagnostic solution.

Accudata Systems and Solis Mammography announced a new partnership with the creation of Center-in-a-Box, a technology solution that supports the rapid deployment of breast screening and diagnostic service. Combining IT design, engineering, equipment installation, and go-live support into one full-service package, Center-in-a-Box is forecasted to grow Solis by approximately 30 to 60 new mammography centers within the next 24 months.

Brian DiPaolo, the chief technology officer of Accudata Systems, tells InnovationMap that the product side of the solution includes equipment for a healthcare clinic, network and security infrastructure, as well as computers, tablets, phones, printers, scanners, and more.

"What differentiates Accudata is the services we provide," says DiPaolo. "From procurement and project management to design, installation, and ongoing support, Accudata is a one-stop shop for turning up a new site quickly."

According to a news release, there is a great demand to provide more centers nationwide, Solis saw the need for innovation and a cost-effective solution and turned to Accudata for assistance. In partnership with Solis, Accudata created a full-service solution for the IT design, equipment, and deployment of one clinic.

"Accudata identified the business challenge centered around people, processes, and products," says DiPaolo. "Solis was unable to scale quickly, limited resources could not provide adequate support, and they did not have the necessary project management and service delivery capabilities. Procurement from different vendors and manufacturers was difficult to manage, and the current network architecture made the process of spinning up new sites difficult and time-consuming."

DiPaolo tells InnovationMap that the company assists Solis when it's time to build out a new clinic or renovate an existing site, first performing a wireless survey to figure out the size of the clinic (small, medium, or large) and the equipment needed. Once this step is complete and the team understands the need, Accudata can begin the process of setting up the equipment in their lab before shipping it to the site and completing the deployment. The total turnaround time from purchase to clinic go-live is just three weeks.

The partnership creates a powerful match. Accudata Systems, founded in 1982 by Rich Johnson and Terry Dickson, is one of the largest IT integrators in the United States with 136 Houston-based employees, as well as a few in San Antonio and Austin and 30 in Dallas. Solis Mammography is the nation's largest independent provider of breast screening and diagnostic services with more than 50 centers in Texas, Arizona, Ohio, North Carolina, Pennsylvania, Washington, D.C, Maryland, and Virginia.

"According to the World Health Organization, breast cancer is the most frequent cancer among women, impacting 2.1 million women each year," says Solis Chief Information Officer Guhan Raghu in a news release. "Breast cancer rates are increasing in nearly every region globally, making the screening and diagnostic services Solis provides ever more vital to early diagnosis and treatment. The Center-in-a-Box IT solution developed with Accudata allows Solis to rapidly address mammography needs across the United States and further fulfill our promise to help women achieve and maintain breast health and peace of mind."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New UH survey reveals concerns over AI data center growth in Houston

data findings

A new report out of the University of Houston shows that area residents remain wary of the long-term effects of operating data centers.

The recent survey from the University of Houston’s latest SPACE City Panel, conducted by the Center for Public Policy at the Hobby School of Public Affairs, shows that while 85 percent of Houston-area residents use AI, nearly 63 percent oppose the construction of AI data centers within 1 mile of their homes.

Respondents’ concerns centered around data centers’ high energy demand and the area’s power grid reliability. According to the survey, 32 percent of residents who oppose local data center projects would be more likely to support the centers if they relied on renewable energy over fossil fuels.

“Respondents understand that AI can bring economic and educational benefits, but they are also concerned about the physical infrastructure needed to fuel AI, especially data centers,” Soran Mohtadi, post-doctoral fellow at the Hobby School and a researcher on the report, said in a news release. “This physical infrastructure demands more electricity and water, leading to environmental impacts.”

Experts estimate that 6.5 gigawatts of data center capacity will be added to the Texas grid by 2030. And Houston’s data center capacity is predicted to more than double by 2028.

The Electric Reliability Council of Texas also projects electricity demand could reach 218 gigawatts by 2031, which would be more than double the record peak set in August 2023. Data centers are expected to account for 86 gigawatts of that new demand.

Survey respondents also said they are concerned about the state's future water supply, given the large amounts of water that data centers need to stay cool.

In terms of who’s responsible for that issue, 57.6 percent of respondents said they put the onus on Texas lawmakers, while 31.5 percent say tech companies should be responsible.

Additionally, more than 75 percent of respondents believed that data center developers and technology companies—not residents—should bear the cost of infrastructure upgrades to support data centers.

“Every decision legislators make has implications on residents’ everyday lives and local infrastructure now and in the future,” Maria P. Perez Arguelles, lead researcher on the report and research assistant professor at the Hobby School, added in the news release. “This issue is going to become more important in years to come, so this is just the beginning.”

Read the full report here.

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."
View All Listings